|
Reference
|
Age (years)/gender
|
Onset
|
Proteinuria
|
Hematuria
|
LM
|
IF
|
EM
|
Follow-up
|
|---|
|
4
|
59/M
|
9 mo
|
3.4 g/gCr
|
ND
|
Glomerular TMA
|
ND
|
FPE
|
Proteinuria decreased
|
|
4
|
74/M
|
3 mo
|
2.7 g/gCr
|
ND
|
Glomerular TMA
|
ND
|
FPE
|
Proteinuria decreased
|
|
4
|
56/M
|
7 mo
|
0.16 g/day
|
ND
|
Glomerular TMA
|
ND
|
Focal FPE
|
Dead shortly thereafter
|
|
4
|
62/M
|
3 mo
|
0.5 g/dl
|
+
|
Glomerular TMA
|
IgA, MES
|
Fibrin, SEn and MES
|
Proteinuria resolved
|
|
4
|
61/M
|
5 mo
|
4.6 g/day
|
ND
|
Glomerular TMA
|
ND
|
Focal podocyte injuries
|
ND
|
|
4
|
59/F
|
9 mo
|
0.8 g/day
|
ND
|
Glomerular TMA
|
IgA, MES
|
EDDs, SEn and focally MES
|
Persistent proteinuria
|
|
5
|
70/M
|
2 w
|
6.0 g/gCr
|
ND
|
Glomerular TMA
|
No
|
ND
|
Proteinuria decreased
|
|
9
|
59/M
|
15 mo
|
6.9 g/day
|
−
|
Glomerular TMA
|
IgA, MES and capillary
|
EDDs, sparsely SEn
|
Proteinuria decreased
|
|
10
|
ND/ND
|
ND
|
Nephrotic
|
ND
|
Cryo-GN
|
ND
|
ND
|
ND
|
|
11
|
ND/F
|
ND
|
Nephrotic
|
ND
|
Collapsing GP
|
ND
|
ND
|
ND
|
|
12
|
69/F
|
3 mo
|
3.6 g/day
|
−
|
Glomerular TMA + collapsing GP
|
IgA, capillary
|
SEn widening without EDDs
|
Proteinuria decreased
|
|
13
|
71/M
|
1 mo
|
9.6 g/day
|
ND
|
Focal PGN
|
C3 and IgM, MES and capillary
|
EDDs, sparsely SEn
|
Proteinuria decreased
|
|
14
|
ND/M
|
3 mo
|
3.4 g/gCr
|
ND
|
Glomerular TMA
|
ND
|
ND
|
ND
|
|
14
|
ND/ND
|
1 mo
|
3.2 g/gCr
|
ND
|
Glomerular TMA
|
ND
|
ND
|
ND
|
|
Present case
|
64/M
|
14 mo
|
3.5 g/day
|
+
|
MES PGN + TMA
|
IgA, MES and capillary
|
EDDs, MES and SEn
|
Proteinuria resolved
|
- Foot notes of Table 3.
- Onset means the duration form the start of bevacizumab to the appearance of urinary abnormalities.
- M, male, F, female, LM, light microscopy, Cr, serum creatinine, IgA, immunoglobulin A, IgM, immunoglobulin M, C3, serum complement component 3, IF, immunofluorescence, EM, electron microscopy, TMA, thrombotic microangiopathy, MES, mesangial, SEn, subendothelial, Cryo-GN, cryoglobulinemic glomerulonephritis, GP, glomerulopathy, PGN, proliferative glomerulonephritis, FPE, foot process effacement, EDDs, electron dense deposits, ND, not documented, mo, month(s), w, week(s).
